Digital health startup Transcarent takes Accolade private in $621 million deal

Core Insights - Transcarent has completed the acquisition of Accolade for approximately $621 million, enhancing its digital health offerings [1][2] - Accolade shareholders received$7.03 per share in cash, and the company's stock will no longer be traded on Nasdaq [2] - Transcarent aims to create a new health and care experience by integrating Accolade's capabilities, emphasizing the benefits of their combined resources [3] Company Overview - Transcarent provides at-risk pricing models to self-insured employers, facilitating quick access to care and benefits navigation for employees [3] - As of May, Transcarent has raised around $450 million, achieving a valuation of$2.2 billion [3] - The company was recognized on CNBC's Disruptor 50 list last year, highlighting its innovative approach in the digital health sector [3]